Innovative Presentation by IN8bio at the ASH Annual Meeting
IN8bio, Inc. (Nasdaq: INAB), a pioneering clinical-stage biopharmaceutical firm, is gearing up for a significant event at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. This prestigious event will be hosted from December 7 to December 10 in a vibrant city.
Details of the Presentation
During this dynamic meeting, IN8bio will present a poster featuring their innovative study titled INB-100: Pilot Study of Donor Derived, ex-vivo Expanded/Activated Gamma-Delta T cell Infusion Following Haploidentical Hematopoietic Stem-Cell Transplantation and Post-Transplant Cyclophosphamide. This research reflects the company’s commitment to advancing cancer treatments using gamma-delta T cell therapies.
Who Will Present?
The presentation will be led by Joseph McGuirk, DO, from The University of Kansas Cancer Center, showcasing the significant developments in cellular immunotherapies.
When and Where?
The poster will be displayed on Monday, December 9, from 6:00 PM to 8:00 PM PDT, as part of the session focusing on early-phase clinical trials and toxicities related to cellular immunotherapies.
Understanding Gamma-Delta T Cell Therapies
Gamma-delta T cells are a unique subset of T cells that exhibit remarkable properties, including the ability to discern between healthy and diseased cells. This capability positions gamma-delta T cells as a crucial component in developing targeted immunotherapies. IN8bio's leading program, INB-100, is specifically designed to harness these advanced cellular features for treating patients with acute myeloid leukemia (AML) following stem cell transplants.
Future Implications
The research being presented is groundbreaking, as it has the potential to significantly improve outcomes for patients undergoing stem cell transplants. Additionally, IN8bio is investigating the use of autologous DeltEx DRI gamma-delta T cells, combined with standard care, for treating glioblastoma, a notoriously aggressive form of brain cancer.
Accessing the Research
The abstract for the poster will be made available online, allowing attendees and those interested to gain insights into the findings and methodologies discussed during the ASH meeting. Reprints of the poster will also be shared on the IN8bio website following the presentations, ensuring that this essential information reaches a broader audience interested in advancements in cancer therapies.
About IN8bio
IN8bio is at the forefront of biopharmaceutical innovation, dedicated to developing gamma-delta T cell-based therapies for improving cancer patient outcomes. Their innovative approach aims to offer new hope through advanced immunotherapies. For those interested in learning more about IN8bio's pioneering work, including their research and programs, further information can be accessed through their official channels.
Contact Information
Investors & Company Contacts:
Glenn Schulman, PharmD, MPH
203.494.7411
Email: gdschulman@IN8bio.com
Patrick McCall
IN8bio, Inc.
646.933.5603
Email: pfmccall@IN8bio.com
Media Contact:
Kimberly Ha
KKH Advisors
917.291.5744
Email: kimberly.ha@kkhadvisors.com
Frequently Asked Questions
What is the focus of IN8bio's presentation at ASH?
IN8bio's presentation will focus on innovative gamma-delta T cell therapies, specifically related to their ongoing research in T cell infusions post-stem cell transplantation.
Who is the presenter for the IN8bio session?
The presentation will be led by Dr. Joseph McGuirk from The University of Kansas Cancer Center.
When will the presentation take place?
The presentation is scheduled for Monday, December 9, from 6:00 PM to 8:00 PM PDT at the ASH Annual Meeting.
What are gamma-delta T cells?
Gamma-delta T cells are a specialized group of T cells that can recognize and respond to abnormal tissue, making them a promising avenue for cancer immunotherapy.
Where can I find more information about IN8bio's research?
For comprehensive information about IN8bio and their research projects, visit their official website after the ASH presentation.
